Program
Anti-Claudin 6 Antibody-drug Conjugate AT03-65
Its studies are led by Axcynsis Therapeutics Pte.
Furthest: phase 1, since Jan 24, 20251 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Axcynsis Therapeutics Pte | 11 open or running | phase 1since Jan 24, 2025 | Jan 24, 2025 | Dec 2027phase 1 · NCT06809114 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 24, 2025First study: phase 1 study in Solid TumorFirst studyNCT06809114 · 83 planned · United States
Ahead
- Dec 2027Primary completion: phase 1 study in Solid TumorNCT06809114
TargetBeta
CLDN6 →read by rule
“An antibody-drug conjugate (ADC) consisting of a recombinant monoclonal antibody directed against the tumor-associated antigen (TAA) claudin 6 (CLDN6; CLDN-6) ”NCIt, by rule
Other programs on CLDN6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ixotatug vedotinrule | torl-biotherapeutics-llc | phase 2 | 3 |
| CLDN6 RNA-LPX Vaccinerule | BioNTech | phase 2 | 1 |
| Anti-CLDN6/CD3 Bispecific Antibody XmAb541rule | Xencor | phase 1 | 2 |
| Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455rule | BeOne Medicines | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06809114Solid Tumor · United States | 1 | Recruiting | Dec 2027 | 83 |
How it is read
Names in the registry
- “AT03-65”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.